于2026年9月18日，The Goldman Sachs Group, Inc.因结束场外衍生品合约（OTC derivatives contracts）而减持再鼎医药股份，好仓减少。该笔交易属场外衍生品交易，并非在二级市场直接买卖正股。
The Goldman Sachs Group, Inc.此次减持前持有再鼎医药好仓5765.08万股，占比5.07%；减持后持股量为5657.30万股，好仓比例降至4.97%。
于2026年9月18日，The Goldman Sachs Group, Inc.因结束场外衍生品合约（OTC derivatives contracts）而减持再鼎医药股份，好仓减少。该笔交易属场外衍生品交易，并非在二级市场直接买卖正股。
The Goldman Sachs Group, Inc.此次减持前持有再鼎医药好仓5765.08万股，占比5.07%；减持后持股量为5657.30万股，好仓比例降至4.97%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.